newsfilter
← Latest News
GlobeNewswire·

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angion Biom